Peroxisome proliferator-activated receptor alpha (PPARα)
Peroxisome proliferator-activated receptor alpha (PPARα), encoded by the PPARA gene, is a ligand-activated transcription factor belonging to the nuclear receptor superfamily.
Peroxisome proliferator-activated receptor alpha (PPARα), encoded by the PPARA gene, is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. It is expressed predominantly in tissues with high rates of fatty acid catabolism, including the liver, heart, skeletal muscle, and kidney. Upon activation by endogenous lipid ligands or synthetic agonists such as fibrate-class drugs, PPARα forms a heterodimer with the retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, thereby orchestrating the transcriptional programs governing fatty acid uptake, mitochondrial and peroxisomal β-oxidation, ketogenesis, and lipoprotein metabolism. Its central role in maintaining hepatic and systemic lipid homeostasis makes it a high-priority pharmacological target in metabolic liver diseases, dyslipidemia, and related cardiometabolic conditions.
Beyond its canonical lipid-regulatory functions, PPARα intersects with inflammatory signaling, mitochondrial quality control, and oxidative stress response pathways. It operates within a broader metabolic regulatory network alongside complementary nuclear receptors such as Peroxisome proliferator-activated receptor gamma (PPARγ), deacetylases such as Sirtuin 1 (SIRT1) (Sirt1), and antioxidant transcription factors such as nuclear factor erythroid 2-related factor 2 (Nrf2). Dysregulation of PPARα activity has been linked to non-alcoholic and metabolic dysfunction–associated steatotic liver disease (MASLD), diabetic nephropathy, aging-related renal fibrosis, and dyslipidemia, underscoring its broad translational relevance.
Where the papers sit
10 papers from the last 6 months study Peroxisome proliferator-activated receptor alpha (PPARα) directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 10 preclinical
Themes 3 themes · 1 new direction
-
PPARα and Lipid Homeostasis
PPARα activation is being pursued to restore lipid balance and protect against metabolic organ injury. MASLD, alcohol-associated and cholestatic liver disease recur as targets, with reported effects on AMPK, PI3K/AKT, CYP4A14, arachidonic acid metabolism and gut microbes. Herbal formulations and other interventions generally converge on reduced hepatic lipid deposition and oxidative injury. Renal mitochondrial dysfunction appears as a related but less developed extension of this protective strategy.
6 papers · 60%
-
Insulin Resistance and Lipid Metabolism
Fatty-acid handling is linked to insulin resistance across diabetic cardiomyopathy and gut-related metabolic dysfunction. In cardiomyocytes, the Airn-QKI-PPARα axis supports fatty-acid oxidation and limits diabetic injury. In diarrhea-predominant IBS, gut bacteria producing fatty-acid ethanolamides are associated with improved insulin resistance. The work remains mechanistically early, connecting RNA regulation and microbial metabolites rather than establishing a shared therapeutic approach.
2 papers · 20%
-
Lipid Metabolism in Renal Cancer
Sunitinib resistance in renal cell carcinoma is increasingly framed as a lipid-metabolic adaptation rather than solely a kinase-response problem. ALOX5 and LGALS1 are linked to fatty-acid reprogramming, with the p38/ERK/PPARα axis and CPT1A implicated in resistant cells. These findings point toward metabolic vulnerabilities that could complement sunitinib or overcome resistance. Whether targeting these pathways improves treatment response remains open.
2 papers · 20%
PPARα is positioned as a regulator of peripheral serotonin handling in IBS-D rather than primarily as a mediator of lipid metabolism
The gut-microbe-derived fatty acid ethanolamide study in diarrhea-predominant irritable bowel syndrome with insulin resistance 42320473Jun assumes the established use of PPARα as a metabolic target but finds that oleoylethanolamide activates PPARα to increase serotonin transporter expression, thereby limiting peripheral serotonin and reducing diarrhea and visceral hypersensitivity in mice. This assigns PPARα a distinct gut–serotonin regulatory role and identifies the PPARα–SERT axis, rather than lipid homeostasis alone, as a therapeutic mechanism for IBS-D with insulin resistance.
Papers
The 10 papers from the last 6 months that study Peroxisome proliferator-activated receptor alpha (PPARα) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
PPARα and Lipid Homeostasis (6)
- Ya-Jie-Sha-Ba Decoction Regulates Arachidonic Acid Metabolism to Treat Alcohol-Associated Liver Disease by Activating PPARα-CYP4A14 Axis: Insights From Multi-Omics Analysis and Experimental Validations. Journal of cellular and molecular medicine · 30 Sept 2026 PMID 42811436
- SIRT1 regulates CaOx crystal-induced exacerbation of renal mitochondrial dysfunction and fibrosis through PPAR-α in aged mice. Journal of molecular medicine (Berlin, Germany) · 28 May 2026 PMID 42209799
- Self-assembling gardenia pectin gel for cholestatic liver injury: Dual mechanisms of hepatoprotection via PPARα activation and gut microbial modulation. Carbohydrate polymers · 7 May 2026 PMID 42097772
- Multi-omics reveals the role of PPARα signaling in the treatment of hyperlipidemia with Qinlian Hongqu Decoction. Journal of pharmaceutical and biomedical analysis · 7 May 2026 PMID 42096839
- Cathepsin G Promotes Hepatic Lipid Deposition by Regulating Key Genes Related to Lipid Metabolism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 17 Apr 2026 PMID 41996208
- Miao medicine Jinshanxiaoke granules alleviates MASLD via Ampk/Ppar-α and Pi3k/Akt-mediated restoration of hepatic lipid homeostasis. Journal of ethnopharmacology · 16 Apr 2026 PMID 41990925
Insulin Resistance and Lipid Metabolism (2)
- LncRNA Airn preserves cardiomyocyte fatty acid oxidation to ameliorate diabetic cardiomyopathy by modulating the QKI-PPARα axis. Redox biology · 28 Aug 2026 PMID 42664805
- Gut bacteria that produce fatty acid ethanolamides alleviate diarrhea-predominant IBS with insulin resistance. Cell host & microbe · 19 Jun 2026 PMID 42320473
Lipid Metabolism in Renal Cancer (2)
- LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism. International immunopharmacology · 20 Jun 2026 PMID 42322858
- ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International immunopharmacology · 13 Jun 2026 PMID 42287957
By study type
Preclinical: animal, cell and lab studies (10)
- Ya-Jie-Sha-Ba Decoction Regulates Arachidonic Acid Metabolism to Treat Alcohol-Associated Liver Disease by Activating PPARα-CYP4A14 Axis: Insights From Multi-Omics Analysis and Experimental Validations. Journal of cellular and molecular medicine · 30 Sept 2026 PMID 42811436
- LncRNA Airn preserves cardiomyocyte fatty acid oxidation to ameliorate diabetic cardiomyopathy by modulating the QKI-PPARα axis. Redox biology · 28 Aug 2026 PMID 42664805
- LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism. International immunopharmacology · 20 Jun 2026 PMID 42322858
- Gut bacteria that produce fatty acid ethanolamides alleviate diarrhea-predominant IBS with insulin resistance. Cell host & microbe · 19 Jun 2026 PMID 42320473
- ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis. International immunopharmacology · 13 Jun 2026 PMID 42287957
- SIRT1 regulates CaOx crystal-induced exacerbation of renal mitochondrial dysfunction and fibrosis through PPAR-α in aged mice. Journal of molecular medicine (Berlin, Germany) · 28 May 2026 PMID 42209799
- Self-assembling gardenia pectin gel for cholestatic liver injury: Dual mechanisms of hepatoprotection via PPARα activation and gut microbial modulation. Carbohydrate polymers · 7 May 2026 PMID 42097772
- Multi-omics reveals the role of PPARα signaling in the treatment of hyperlipidemia with Qinlian Hongqu Decoction. Journal of pharmaceutical and biomedical analysis · 7 May 2026 PMID 42096839
- Cathepsin G Promotes Hepatic Lipid Deposition by Regulating Key Genes Related to Lipid Metabolism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 17 Apr 2026 PMID 41996208
- Miao medicine Jinshanxiaoke granules alleviates MASLD via Ampk/Ppar-α and Pi3k/Akt-mediated restoration of hepatic lipid homeostasis. Journal of ethnopharmacology · 16 Apr 2026 PMID 41990925
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.